ReviewMediators of inflammation2009
Cellular mediators of inflammation: tregs and TH17 cells in gastrointestinal diseases.
Review in Mediators of inflammation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Gut microbiome and nutritional strategies in gastrointestinal cancers: Clinical implications and therapeutic perspectives.World journal of clinical oncology · 2025Review
- Limited Proteolysis as a Regulator of Lymphatic Vessel Function and Architecture.International journal of molecular sciences · 2025Review
- Andrographolide derivative CX-10 alleviates ulcerative colitis by modulating autophagy and cellular stress.Journal of clinical biochemistry and nutrition · 2025Article
- Gut Microbiota, Inflammatory Bowel Disease, and Cancer: The Role of Guardians of Innate Immunity.Cells · 2023Review
- The Role of Gut Microbiota in Heart Failure: When Friends Become Enemies.Biomedicines · 2022Review
- Carbamylated erythropoietin regulates immune responses and promotes long-term kidney allograft survival through activation of PI3K/AKT signaling.Signal transduction and targeted therapy · 2020Article
- Influence of microbiota on immunity and immunotherapy for gastric and esophageal cancers.Gastroenterology report · 2020Review
- Microtopography of Immune Cells in Osteoporosis and Bone Lesions by Endocrine Disruptors.Frontiers in immunology · 2020Review
- The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer.International journal of molecular sciences · 2019Review
- The Intricate Link among Gut "Immunological Niche," Microbiota, and Xenobiotics in Intestinal Pathology.Mediators of inflammation · 2017Review
- Review
- The Interactions between Innate Immunity and Microbiota in Gastrointestinal Diseases.Journal of immunology research · 2015Article
- The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis.Analytical cellular pathology (Amsterdam) · 2015Review
- How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology.Journal of immunology research · 2015Review
- The Interaction among Microbiota, Immunity, and Genetic and Dietary Factors Is the Condicio Sine Qua Non Celiac Disease Can Develop.Journal of immunology research · 2015Review
- Uncomplicated diverticular disease: innate and adaptive immunity in human gut mucosa before and after rifaximin.Journal of immunology research · 2014Article
- Effect of Th17 and Treg axis disorder on outcomes of pulmonary arterial hypertension in connective tissue diseases.Mediators of inflammation · 2014Article
- Tissue-infiltrating lymphocytes analysis reveals large modifications of the duodenal "immunological niche" in coeliac disease after gluten-free diet.Clinical and translational gastroenterology · 2012Article
- Gut microbiota and inflammation.Nutrients · 2011Review
- The immune response to tumors as a tool toward immunotherapy.Clinical & developmental immunology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human lymphocyte subpopulations were originally classified as T- and B-cells in the 70s. Later, with the development of monoclonal antibodies, it became possible to recognize, within the T-cells, functional populations: CD4(+) and CD8(+). These populations were usually referred to as "helper" and "suppressor" cells, respectively. However several investigations within the CD8 cells failed to detect a true suppressor activity. Therefore the term suppressor was neglected because it generated confusion. Much later, true suppressor activity was recognized in a subpopulation of CD4 cells characterized by high levels of CD25. The novel population is usually referred to as T regulatory cells (Tregs) and it is characterized by the expression of FoxP3. The heterogeneity of CD4 cells was further expanded by the recent description of a novel subpopulation characterized by production of IL-17. These cells are generally referred to as T(H)17. They contribute to regulate the overall immune response together with other cytokine-producing populations. Treg and T(H)17 cells are related because they could derive from a common progenitor, depending on the presence of certain cytokines. The purpose of this review is to summarize recent findings of the role of these novel populations in the field of human gastroenterological disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.